Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 7/20 | 0.61 |
| ▸ | CDK8 | P49336 | 7/20 | 0.61 |
| ▸ | CDK19 | Q9BWU1 | 7/20 | 0.61 |
| ▸ | CDK2 | P24941 | 11/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.46 |
| ▸ | AURKA | O14965 | 6/20 | 0.46 |
| ▸ | PLK1 | P53350 | 5/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCND3 | P30281 | 2/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.46 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247111 | 0.85 | CCNA2 (0.49) | CCNCCDK8CDK19CDK2CCNA2 | |
| SCHEMBL7243148 | 0.80 | CCNC (0.62) | CCNCCDK8CDK19CDK2CCNA2 | |
| SCHEMBL7041310 | 0.80 | CCNC (0.72) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7038741 | 0.79 | CCNC (0.73) | CCNCCDK8CDK19PLK1DRD2 | |
| SCHEMBL7039119 | 0.79 | CCNC (0.61) | CCNCCDK8CDK19CDK2CCNA2 | |
| SCHEMBL7241539 | 0.79 | CCNC (0.72) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL6998214 | 0.78 | CCNC (0.57) | CCNCCDK8CDK19CDK2CCNA2 | |
| SCHEMBL7242470 | 0.77 | CCNC (0.58) | CCNCCDK8CDK19CDK2CCNA2 | |
| SCHEMBL7243070 | 0.76 | CCNC (0.68) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7243019 | 0.74 | CCNC (0.68) | CCNCCDK8CDK19CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617726-A1 | DIABETES THERAPEUTIC AGENT | Takeda Pharmaceutical Company Limited (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184272-A1 | DIABETES THERAPEUTIC AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184272-A1 | DIABETES THERAPEUTIC AGENT | FABP4, GPR119, CPT1B | CCNC 3196/4885CDK8 4502/4885CDK19 4521/4885 |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | CCNC 2012/4885CDK8 3614/4885CDK19 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.